Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer

Pancreas

Volumn 42, Issue 7, 2013, Pages 1143-1149

  Niu, Lizhi ^a   Chen, Jibing ^a   He, Lihua ^a   Liao, Mengtian ^a   Yuan, Yuanying ^a   Zeng, Jianying ^a   Li, Jialiang ^a   Zuo, Jiansheng ^a   Xu, Kecheng ^a  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

cryoablation; dendritic cell cytokine induced killer cell method; immunotherapy; metastatic pancreatic cancer

Indexed keywords

AMYLASE; ANTINEOPLASTIC AGENT; GLUCOSE;

ABDOMINAL BLEEDING; ABDOMINAL DISTENSION; ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; ASCITES; BORDERLINE HYPERTENSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CORONARY ARTERY DISEASE; CRYOABLATION; CRYOSURGERY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYDROTHORAX; LIVER METASTASIS; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PANCREAS CANCER; POSTOPERATIVE NAUSEA; PRIORITY JOURNAL; REPEAT PROCEDURE; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COMBINED MODALITY THERAPY; CRYOSURGERY; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84885173366     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182965dde     Document Type: Article

References (48)

1. Siegel R,Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
3. Wolff RA. Chemotherapy for pancreatic cancer: from metastatic disease to adjuvant therapy. Cancer J. 2007;13(3):175-184.
4. Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82.
5. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-1966. (Pubitemid 46972777)
6. Spiliotis JD, Datsis AC, Michalopoulos NV, et al. Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas. Langenbecks Arch Surg. 2007;392(1):55-60. (Pubitemid 46147485)
7. Zou YP, Li WM, Zheng F, et al. Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J Gastroenterol. 2010;16(40):5104-5110.
8. Xu KC, Niu LZ, Hu YZ, et al. A pilot study on combination of cryosurgery and (125)iodine seed implantation for treatment of locally advanced pancreatic cancer. World J Gastroenterol. 2008;14(10):1603-1611.
9. Xu KC, Niu LZ, Hu YZ, et al. Cryosurgery with combination of (125)iodine seed implantation for the treatment of locally advanced pancreatic cancer. J Dig Dis. 2008;9(1):32-40. (Pubitemid 351188938)
10. Kimura Y, Tsukada J, Tomoda T, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012;41(2):195-205.
11. Hirooka Y, Itoh A, Kawashima H, et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas. 2009;38(3):e69Ye74.
12. Kondo H, Hazama S, Kawaoka T, et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res. 2008;28(1B):379-387. (Pubitemid 351362841)
13. Koido S, Homma S, Takahara A, et al. Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol. 2011;2011:267539.
14. Kaneko T, Goto S, Kato A, et al. Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer. Anticancer Res. 2005;25(6A):3709-3714. (Pubitemid 41658443)
15. Nakamura M, Wada J, Suzuki H, et al. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer. Anticancer Res. 2009;29(3):831-836.
16. Katari UL, Keirnan JM, Worth AC, et al. Engineered T cells for pancreatic cancer treatment. HPB (Oxford). 2011;13(9):643-650.
17. Tokh M, Bathini V, Saif MW. First-line treatment of metastatic pancreatic cancer. JOP. 2012;13(2):159-162.
18. Marten A, Buchler MW. Immunotherapy of pancreatic carcinoma. Curr Opin Investig Drugs. 2008;9(6):565-569. (Pubitemid 351777159)
19. Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology. 2009;58(1):1-11.
20. Rovere-Querini P, Manfredi AA. Tumor destruction and in situ delivery of antigen presenting cells promote anti-neoplastic immune responses: implications for the immunotherapy of pancreatic cancer. JOP. 2004;5(4):308-314. (Pubitemid 41573884)
21. Thanendrarajan S, Nowak M, Abken H, et al. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res. 2011;35(9):1136-1142.
22. Marten A, Ziske C, Schottker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother. 2001;24(6):502-510. (Pubitemid 33104869)
23. Yang XJ, Huang JA, Lei W, et al. Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on lung cancer in vitro and in vivo [in Chinese]. Ai Zheng. 2006;25(11):1329-1333.
24. Wongkajornsilp A, Sangsuriyong S, Hongeng S, et al. Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells. J Orthop Res. 2005;23(6):1460-1466. (Pubitemid 41554683)
25. Wei XC, Zhai XH, Han XR, et al. Biological activity of DC-CIK cells and its effect against leukemia cells in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16(5):1150-1153.
26. Ge W, Li CH, Zhang W, et al. Coculture of dendritic cell with cytokine-induced killer results in a significant increase in cytotoxic activity of CIK to tumor cells in vitro and in vivo [in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2004;25(5):277-280.
27. Wang H, Zhou FJ, Wang QJ, et al. Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinomaYa report of ten cases [in Chinese]. Ai Zheng. 2006;25(5):625-630.
28. Su X, Zhang L, Jin L, et al. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells. J Clin Immunol. 2010;30(5):766-774.
29. Marten A, Renoth S, von Lilienfeld-Toal M, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica. 2001;86(10):1029-1037. (Pubitemid 33031868)
30. Gonzalez-Carmona MA, Marten A, Hoffmann P, et al. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int. 2006;26(3):369-379. (Pubitemid 43349329)
31. Li H, Wang C, Yu J, et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy. 2009;11(8):1076-1083.
32. Xu K, Zhou L, Liang B, et al. Safety and accuracy of percutaneous core needle biopsy in examining pancreatic neoplasms. Pancreas. 2012;41(4):649-651.
33. Xu KC, Niu LZ, Zhou Q, et al. Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World J Gastroenterol. 2009;15(29):3664-3669.
34. Azizi A, Naguib NN, Mbalisike E, et al. Liver metastases of pancreatic cancer: role of repetitive transarterial chemoembolization (TACE) on tumor response and survival. Pancreas. 2011;40(8):1271-1275.
35. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403- 2413. (Pubitemid 27251144)
36. Okada S, Ueno H, Okusaka T, et al. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 2001;31(1):7-12. (Pubitemid 32236880)
37. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
38. Koido S, Homma S, Takahara A, et al. Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. Immunotherapy. 2012;4(1):5-7.
39. Plate J. Clinical trials of vaccines for immunotherapy in pancreatic cancer. Expert Rev Vaccines. 2011;10(6):825-836.
40. Schnurr M, Scholz C, Rothenfusser S, et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res. 2002;62(8):2347-2352. (Pubitemid 34411716)
41. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296.
42. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4(3):328-332. (Pubitemid 28144092)
43. Mackensen A, Herbst B, Chen JL, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer. 2000;86(3):385-392. (Pubitemid 30187500)
44. Palucka AK, Ueno H, Connolly J, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006;29(5):545-557. (Pubitemid 44395279)
45. Nair SK, Boczkowski D, Morse M, et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998;16(4):364-369. (Pubitemid 28164657)
46. Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine. 1999;18(9-10):765-777.
47. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004;199:251-263. (Pubitemid 38744521)
48. Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3(5):558-561. (Pubitemid 27198656)